StockrabitBrowse analysts
Analyst questions

Meet Bhuva

Integrity Ventures and Partnerships
MARKSANS

Marksans Pharma Limited

All company calls
FY2027 Q1
13 Aug 2026
Open call
  1. Yeah, hi. Am I audible?

    Read in transcript
  2. Yeah, hi, sir. Congratulations on a great set of numbers first of all. And I have a couple of questions. So, we have clocked around 25% on the bottom -line in quarter one. So like -- and also, we have guided for FY27 revenue growth of 15% to 20% and 20% to 21% EBITDA margin. So, is there any plan to revise based on the upward side, or how should we look at it?

    Read in transcript
  3. Okay. And the next question is on this quarter, our U.K. and Europe segment grow like around 74% Y-o-Y and 15% quarter-on-quarter. So how sustainable growth we can assume in these two markets?

    Read in transcript
+3 more questions in this call